GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

relzasertideg   Click here for help

GtoPdb Ligand ID: 14363

Synonyms: BMS-986397 | BMS986397 | CC-91633 [3] | CC91633 | compound 173 [WO2020243379] | example 25 [WO2020243379]
Compound class: Synthetic organic
Comment: The chemical structure for this compound was obtained from WHO INN proposed list 134 (Feb 2026), in which it is described as a serine/threonine kinase degradation inducer with antineoplastic potential. A structure search in PubChem suggests that this is the INN for BMS-986397, a lead casein kinase 1α (CK1α) degrader [2]. Claimed in Celgene Corp. patent WO2020243379A1 [1]. Relzasertideg targets CK1α for CRL4CRBN E3 ubiquitin ligase-mediated degradation.
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 8
Hydrogen bond donors 2
Rotatable bonds 6
Topological polar surface area 107.94
Molecular weight 480.83
XLogP 0.45
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES C1=CN=C(C(=C1)Cl)[C@H](C(F)(F)F)NC(=O)C2=CC=C3C(=C2)CN([C@H]4CCC(=O)NC4=O)C3=O
Isomeric SMILES C1CC(=O)NC(=O)[C@H]1N2CC3=C(C2=O)C=CC(=C3)C(=O)N[C@H](C4=C(C=CC=N4)Cl)C(F)(F)F
InChI InChI=1S/C21H16ClF3N4O4/c22-13-2-1-7-26-16(13)17(21(23,24)25)28-18(31)10-3-4-12-11(8-10)9-29(20(12)33)14-5-6-15(30)27-19(14)32/h1-4,7-8,14,17H,5-6,9H2,(H,28,31)(H,27,30,32)/t14-,17+/m0/s1
InChI Key DGAWFEDONPXNNP-WMLDXEAASA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
A CK1α-targeting CELMoD (novel thalidomide analog) agent that was proposed for treatment of relapsed/refractory high-risk Myelodysplastic syndromes and relapsed/refractory acute myeloid leukaemia. Development was terminated in response to unfavourable results from a phase 1 trial [2].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04951778 Study to Evaluate Safety and Tolerability of CC-91633 (BMS-986397) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes Phase 1 Interventional Celgene 2